Trump Eyes Drug Tariffs-What It Means for K-Bio

[Kim Jinsoo, Edaily Reporter] President Donald Trump is preparing to impose tariffs on pharmaceuticals as part of his protectionist trade agenda, raising concerns among South Korean biopharma companies that rely heavily on the U.S.

◇SK Biopharmaceuticals: Ahead of the Curve SK Biopharmaceuticals, which is banking on its epilepsy drug Xcopri to become a blockbuster, appears largely insulated from tariff impacts.

While API manufacturing still takes place in Korea and the tablets are packaged in Canada before reaching the U.S., SK Biopharmaceuticals has long pursued a U.S.